Official UK procurement notice
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
Authority: Belfast Health & Social Care Trust (Central government)
What is being bought
Published requirement descriptionProcurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
CPV: Medical equipments, pharmaceuticals and personal care products
The lotProcurement structure
single lot · no lot value publishedLot #1
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- Price
Procedure terms & legal framework
From the official record- Procedure method
- Negotiated without publication of a contract notice
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 9 May 2022, 17:52 BST
- Last source update
- 9 May 2022, 17:52 BST
- Authority reference
DAC10464- FTS notice number
2022/S 000-012066- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0335bfFind a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
- Published justification
No other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (177Lu) oxodetreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Advanced Accelerator Applications (UK and Ireland) Ltd | £1,000,000 † | — | Awarded |
Contracts
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT · Advanced Accelerator Applications (UK and Ireland) Ltd
- Signed
- 9 May 2022
- Value
- £1,000,000
- Status
- active
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- Advanced Accelerator Applications (UK & Ireland) LtdAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.